Advanced

Prostate kallikrein markers in diagnosis, risk stratification and prognosis.

Ulmert, David LU ; O'Brien, M Frank; Bjartell, Anders LU and Lilja, Hans LU (2009) In Nature Reviews Urology 6(7). p.384-391
Abstract
The kallikrein, prostate-specific antigen (PSA), is one of the world's most frequently used disease biomarkers. After almost two decades of research and clinical experience, the diagnostic and monitoring limitations of PSA are beginning to be understood. Most physicians are aware of PSA's low specificity for cancer among older men with benign prostatic conditions; fewer are aware of recent data, which show that a prior negative biopsy or a prior PSA value below the threshold for biopsy might compromise the predictive accuracy of PSA even further. Furthermore, a subtle increase in serum PSA level during early middle age is strongly correlated with clinically important prostate cancer. We review current and past reports on the prostate... (More)
The kallikrein, prostate-specific antigen (PSA), is one of the world's most frequently used disease biomarkers. After almost two decades of research and clinical experience, the diagnostic and monitoring limitations of PSA are beginning to be understood. Most physicians are aware of PSA's low specificity for cancer among older men with benign prostatic conditions; fewer are aware of recent data, which show that a prior negative biopsy or a prior PSA value below the threshold for biopsy might compromise the predictive accuracy of PSA even further. Furthermore, a subtle increase in serum PSA level during early middle age is strongly correlated with clinically important prostate cancer. We review current and past reports on the prostate kallikreins PSA and hK2 in relation to pathology and epidemiology. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Nature Reviews Urology
volume
6
issue
7
pages
384 - 391
publisher
Nature Publishing Group
external identifiers
  • wos:000267784600011
  • pmid:19578355
  • scopus:74949139859
ISSN
1759-4820
DOI
10.1038/nrurol.2009.123
language
English
LU publication?
yes
id
46ba6bc7-99e1-401b-b038-4448e8f09e28 (old id 1453393)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/19578355?dopt=Abstract
date added to LUP
2009-08-04 10:27:28
date last changed
2017-01-01 07:32:20
@article{46ba6bc7-99e1-401b-b038-4448e8f09e28,
  abstract     = {The kallikrein, prostate-specific antigen (PSA), is one of the world's most frequently used disease biomarkers. After almost two decades of research and clinical experience, the diagnostic and monitoring limitations of PSA are beginning to be understood. Most physicians are aware of PSA's low specificity for cancer among older men with benign prostatic conditions; fewer are aware of recent data, which show that a prior negative biopsy or a prior PSA value below the threshold for biopsy might compromise the predictive accuracy of PSA even further. Furthermore, a subtle increase in serum PSA level during early middle age is strongly correlated with clinically important prostate cancer. We review current and past reports on the prostate kallikreins PSA and hK2 in relation to pathology and epidemiology.},
  author       = {Ulmert, David and O'Brien, M Frank and Bjartell, Anders and Lilja, Hans},
  issn         = {1759-4820},
  language     = {eng},
  number       = {7},
  pages        = {384--391},
  publisher    = {Nature Publishing Group},
  series       = {Nature Reviews Urology},
  title        = {Prostate kallikrein markers in diagnosis, risk stratification and prognosis.},
  url          = {http://dx.doi.org/10.1038/nrurol.2009.123},
  volume       = {6},
  year         = {2009},
}